Inventor · disambiguated record
Andrew J. Souers
Also filed as: SOUERS ANDREW · SOUERS ANDREW J
63 granted patents·75 pending applications·803 citations·filing 2003–2024
99Inventor score
Top patents by PatentIndex Score
138 records- 0198US8546399B2Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseasesBRUNCKO MILAN·Filed 2010·Granted Oct 1, 2013·100 cites·24 claims
- 0297US9174982B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2013·Granted Nov 3, 2015·38 cites·7 claims
- 0397US8586754B2BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseasesBRUNCKO MILAN·Filed 2010·Granted Nov 19, 2013·59 cites·8 claims
- 0497US8580794B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesDOHERTY GEORGE A·Filed 2010·Granted Nov 12, 2013·44 cites·3 claims
- 0597US8563735B2Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseasesBRUNCKO MILAN·Filed 2009·Granted Oct 22, 2013·72 cites·4 claims
- 0696US9034875B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2013·Granted May 19, 2015·19 cites·1 claims
- 0796US9029404B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2013·Granted May 12, 2015·19 cites·1 claims
- 0895US8343967B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBOTT LAB·Filed 2012·Granted Jan 1, 2013·32 cites·2 claims
- 0995US8114893B2Compounds and methods of useBAELL JONATHAN BAYLDON·Filed 2009·Granted Feb 14, 2012·43 cites·20 claims
- 1094US9315488B2Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseasesABBVIE INC·Filed 2015·Granted Apr 19, 2016·13 cites·2 claims
- 1194US9073855B2BCL-2 selective apoptosis-inducing agents for the treatment of cancer and immune diseasesABBVIE INC·Filed 2013·Granted Jul 7, 2015·11 cites·2 claims
- 1294US9045420B2Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseasesABBVIE INC·Filed 2013·Granted Jun 2, 2015·11 cites·1 claims
- 1394US9045475B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2013·Granted Jun 2, 2015·14 cites·2 claims
- 1494US8952157B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2013·Granted Feb 10, 2015·22 cites·5 claims
- 1594US8426422B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesHEXAMER LAURA A·Filed 2010·Granted Apr 23, 2013·49 cites·4 claims
- 1693US8883784B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2013·Granted Nov 11, 2014·11 cites·14 claims
- 1793US8518970B2Compounds and methods of useBAELL JONATHAN BAYLDON·Filed 2012·Granted Aug 27, 2013·29 cites·25 claims
- 1892US9403822B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2015·Granted Aug 2, 2016·9 cites·6 claims
- 1992US8940737B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2012·Granted Jan 27, 2015·7 cites·10 claims
- 2092US8232273B2Heterocyclic compounds and methods of useBAELL JONATHAN BAYLDON·Filed 2009·Granted Jul 31, 2012·28 cites·31 claims
- 2192US6989392B22-Aminoquinolines as melanin concentrating hormone receptor antagonistsABBOTT LAB·Filed 2003·Granted Jan 24, 2006·39 cites·14 claims
- 2291US9303025B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2014·Granted Apr 5, 2016·11 cites·4 claims
- 2391US8338466B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesKUNZER AARON R·Filed 2010·Granted Dec 25, 2012·15 cites·6 claims
- 2490US9072748B2BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseasesABBVIE INC·Filed 2013·Granted Jul 7, 2015·11 cites·10 claims
- 2589US11964990B21,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitorsABBVIE INC·Filed 2023·Granted Apr 23, 2024·1 cites·2 claims
- 2689US10676485B2Macrocyclic MCL-1 inhibitors and methods of useABBVIE INC·Filed 2018·Granted Jun 9, 2020·2 cites·2 claims
- 2789US9125913B2Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseasesABBVIE INC·Filed 2013·Granted Sep 8, 2015·10 cites·6 claims
- 2888US9345702B2Methods of treatment using selective Bcl-2 inhibitorsABBVIE INC·Filed 2014·Granted May 24, 2016·8 cites·12 claims
- 2988US8889675B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2012·Granted Nov 18, 2014·3 cites·9 claims
- 3087US9006247B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesTAO ZHI-FU·Filed 2011·Granted Apr 14, 2015·11 cites·5 claims
- 3187US7981888B21-oxyalkyl-2-carboxyl-7-nonsubstituted indole derivativesABBOTT LAB·Filed 2008·Granted Jul 19, 2011·8 cites·7 claims
- 3287US2024285611A1Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2023·Application pending·0 cites
- 3386US9266877B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2014·Granted Feb 23, 2016·2 cites·2 claims
- 3486US9227963B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2014·Granted Jan 5, 2016·2 cites·2 claims
- 3586US2025313572A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2024·Application pending·0 cites
- 3686US2025019364A1Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2024·Application pending·0 cites
- 3784US10640563B2Anti-B7-H3 antibodies and antibody drug conjugatesABBVIE INC·Filed 2017·Granted May 5, 2020·3 cites·3 claims
- 3884US8188077B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesDING HONG·Filed 2011·Granted May 29, 2012·8 cites·5 claims
- 3984US2025177374A1BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the SameABBVIE INC·Filed 2024·Application pending·0 cites
- 4083US2024043404A1Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2023·Application pending·0 cites
- 4182US11897864B2Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2022·Granted Feb 13, 2024·0 cites·27 claims
- 4282US9067928B2Compounds and methods of useGENENTECH INC·Filed 2013·Granted Jun 30, 2015·5 cites·24 claims
- 4382US2024228509A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2023·Application pending·0 cites
- 4481US2025092062A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2024·Application pending·0 cites
- 4581US2025213685A1Anti-egfr antibody drug conjugatesABBVIE INC·Filed 2024·Application pending·0 cites
- 4681US2025263491A1Anti-egfr antibody drug conjugatesABBVIE INC·Filed 2024·Application pending·0 cites
- 4780US8445679B27-substituted indole MCL-1 inhibitorsWANG XILU·Filed 2008·Granted May 21, 2013·7 cites·4 claims
- 4878US8969375B2CDK9 kinase inhibitorsABBVIE INC·Filed 2014·Granted Mar 3, 2015·2 cites·17 claims
- 4978US2025170263A1Anti-egfr antibody-drug conjugatesABBVIE INC·Filed 2024·Application pending·0 cites
- 5078US2023399340A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2022·Application pending·0 cites
Showing the top 50 of 138 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →